Neuland Laboratories Crescita futura
Criteri Future verificati 4/6
Neuland Laboratories prevede che gli utili e i ricavi cresceranno rispettivamente di 18.6% e 14.5% all'anno. Si prevede che l'EPS crescerà di 18.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 24.4% in 3 anni.
Informazioni chiave
18.6%
Tasso di crescita degli utili
18.44%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.3% |
| Tasso di crescita dei ricavi | 14.5% |
| Rendimento futuro del capitale proprio | 24.45% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 06 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 06
524558: Capacity Plans And Transdermal CDMO Work Will Shape Balanced Future Outlook
Analysts have raised their price target on Neuland Laboratories from ₹20,972 to ₹22,784.50, citing updated assumptions that include a slightly lower discount rate, moderated revenue growth expectations, and a higher profit margin outlook alongside a broadly steady future P/E. What’s in the News for Neuland Laboratories A board meeting is scheduled for August 5, 2026 at 10:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Aggiornamento narrativa • Jun 13
524558: New Leadership And Transdermal CDMO Work Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹20,972, with only marginal tweaks to long term growth, profit margin and future P/E assumptions. As a result, the overall price target remains unchanged.Aggiornamento narrativa • May 30
524558: New CEO And CDMO Focus Will Support Future Upside Potential
Analysts now peg Neuland Laboratories' fair value at ₹20,972, compared with the previous ₹18,852.75, citing updates to long term revenue growth, profit margin assumptions, and a higher future P/E multiple in their models. What's in the News A board meeting is scheduled for May 12, 2026 at 14:15 IST to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for FY 2025-26, along with other matters (Key Developments).Aggiornamento narrativa • May 12
524558: Leadership Transition And CDMO Focus Will Shape Balanced Future Potential
Analysts have trimmed their fair value estimate for Neuland Laboratories slightly from ₹18,865.25 to ₹18,852.75. This reflects small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E multiples.Aggiornamento narrativa • Apr 20
524558: Leadership Transition And Peptide Collaboration Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25, reflecting unchanged views on discount rate, revenue growth, profit margin, and future P/E assumptions that underpin their price target rationale. What's in the News Neuland Laboratories plans a leadership transition, with Saharsh Davuluri set to become Chief Executive Officer from 01 April 2026.Aggiornamento narrativa • Apr 04
524558: Phase 2 Peptide Design Progress Will Support Future Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹18,865.25, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. This signals that the latest review did not alter their core outlook on the stock.Aggiornamento narrativa • Mar 20
524558: Phase 2 Peptide Progress And 2026 Board Meeting Will Support Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25. This reflects unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.Aggiornamento narrativa • Mar 05
524558: Peptide Partnership Progress And Upcoming Results Date Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Neuland Laboratories at ₹18,865.25 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. As a result, this narrative update focuses on reaffirmed conviction rather than a change in the price target.Aggiornamento narrativa • Feb 19
524558: New R&D Center And Peptide Partnership Will Support Future Upside Potential
Analysts have revised their price target for Neuland Laboratories from ₹20,659 to ₹18,865, reflecting updates to their model that now factors in adjusted assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News LIR Life Sciences has started Project Phase 2 peptide design work with Neuland Laboratories, focusing on next generation cell penetrating peptides for its transdermal delivery platform, following completion of Phase 1 synthesis work (Product related announcement).Aggiornamento narrativa • Feb 05
524558: New R&D Center Will Support Future Upside Potential
Analysts have kept their price target for Neuland Laboratories unchanged at ₹20,659, citing consistent assumptions on discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Board meeting scheduled for February 9, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Aggiornamento narrativa • Jan 21
524558: New R&D Center And Peptide Partnership Will Drive Future Upside
Analysts have trimmed their fair value estimate for Neuland Laboratories from ₹20,884 to ₹20,659, citing slightly adjusted views on revenue growth, profit margins and future P/E assumptions while keeping the discount rate unchanged. What's in the News LIR Life Sciences Corp.Aggiornamento narrativa • Jan 06
524558: New R&D Center Capex Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories unchanged at ₹20,884. This steady view is supported by consistent assumptions on discount rate, revenue growth, profit margin and future P/E.Aggiornamento narrativa • Dec 15
524558: New R&D Center Will Drive Future Upside Potential
Narrative Update on Neuland Laboratories Analysts have modestly revised their price target on Neuland Laboratories with a slight adjustment that reflects largely unchanged assumptions around fair value at ₹20,884, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News The board will consider capital expenditure of INR 1,890 million for establishing a new Research and Development Center at the meeting scheduled on November 28, 2025 (Board Meeting).Aggiornamento narrativa • Dec 01
524558: R&D Center and Leadership Changes Will Unlock Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹20,884, citing consistent estimates for future revenue growth and profit margin projections. What's in the News A Board Meeting is scheduled for November 28, 2025 to approve and consider a capital expenditure of INR 1,890 million for setting up a Research & Development (R&D) Center.Aggiornamento narrativa • Nov 17
524558: Executive Leadership Changes Will Drive Future Upside Potential
Analysts have raised their fair value estimate for Neuland Laboratories from ₹17,494.50 to ₹20,884.00. They cite updated assumptions about growth and profitability, despite modest adjustments to revenue growth and profit margin forecasts.Aggiornamento narrativa • Nov 03
524558: Leadership Changes And Board Decisions Will Shape The Next Phase
Analysts have raised their price target for Neuland Laboratories from ₹16,375 to ₹17,494.50. This change reflects updated expectations based on modest adjustments in forecasted revenue growth, profit margin, and valuation multiples.Aggiornamento narrativa • Sep 05
Manufacturing Expansion And Peptide Expertise Will Unlock Future Opportunities
Neuland Laboratories’ target price has been revised upward as a result of a marked increase in its forecast P/E ratio despite a significant decline in net profit margin, now reflecting a new consensus of ₹16,375. What's in the News Special/Extraordinary Shareholders Meeting to be conducted via postal ballot.
Nuova narrativa • Feb 24
Ongoing Capacity Expansions In CDMO And Specialty GDS Set To Strengthen Future Prospects
New facilities and capacity expansion will drive revenue growth and improve operational efficiency by FY '26.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2029 | 34,928 | 8,532 | 6,012 | N/A | 3 |
| 3/31/2028 | 29,266 | 6,265 | 4,045 | N/A | 5 |
| 3/31/2027 | 24,435 | 4,798 | 4,466 | N/A | 5 |
| 6/30/2026 | 23,718 | 4,978 | N/A | N/A | N/A |
| 3/31/2026 | 20,230 | 3,640 | -505 | 3,467 | N/A |
| 12/31/2025 | 15,751 | 1,791 | N/A | N/A | N/A |
| 9/30/2025 | 15,334 | 2,401 | -1,425 | 1,312 | N/A |
| 6/30/2025 | 13,300 | 1,761 | N/A | N/A | N/A |
| 3/31/2025 | 14,768 | 2,601 | 1,109 | 3,174 | N/A |
| 12/31/2024 | 15,335 | 2,999 | N/A | N/A | N/A |
| 9/30/2024 | 15,283 | 2,797 | 413 | 2,457 | N/A |
| 6/30/2024 | 16,352 | 3,361 | N/A | N/A | N/A |
| 3/31/2024 | 15,586 | 3,001 | 1,175 | 2,612 | N/A |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | N/A | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | N/A | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | N/A | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | N/A | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 524558 ( 18.6% all'anno) è superiore al tasso di risparmio ( 6.9% ).
Guadagni vs Mercato: Si prevede che gli utili di 524558 ( 18.6% all'anno) cresceranno più rapidamente del mercato Indian ( 16.8% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 524558 cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di 524558 ( 14.5% all'anno) crescerà più rapidamente del mercato Indian ( 11.1% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 524558 ( 14.5% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 524558 sarà elevato tra 3 anni ( 24.4 %)
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/20 02:54 |
| Prezzo dell'azione a fine giornata | 2026/08/20 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Neuland Laboratories Limited è coperta da 9 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Srivathsan Ramachandran | Avendus Spark |
| Kameswari V. S. Chavali | FirstCall Research |